Adjuvant ovarian ablation vs CMF chemotherapy in premenopausal breast cancer patients: trial update and impact of immunohistochemical assessment of ER status

The Breast ◽  
2002 ◽  
Vol 11 (5) ◽  
pp. 419-429 ◽  
Author(s):  
C.S. Thomson ◽  
C.J. Twelves ◽  
E.A. Mallon ◽  
R.E. Leake
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Premenopausal Breast Cancer ◽  
Ovarian Ablation ◽  
Immunohistochemical Assessment ◽  
Er Status

scholarly journals Major Depression in Breast Cancer Patients with Ovarian Function Suppression: A Cross-Sectional Study Comparing Ovarian Ablation and Gonadotropin-Releasing Hormone Agonists

2021 ◽  
Author(s):  
Junhan Jiang ◽  
Junnan Xu ◽  
Li Cai ◽  
Li Man ◽  
Limin Niu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Major Depression ◽  
Sexual Dysfunction ◽  
Sexual Function ◽  
Cancer Patients ◽  
Gonadotropin Releasing Hormone ◽  
Breast Cancer Patients ◽  
Premenopausal Breast Cancer ◽  
Releasing Hormone ◽  
Ovarian Ablation

Abstract Purpose: We examined whether there were differences in major depression outcomes and independent risk factors associated with gonadotropin-releasing hormone agonists (GnRHa) and ovarian ablation (OA) in premenopausal breast cancer patients. Methods: Premenopausal breast cancer patients from seven hospitals who received OFS participated in the study between June 2019 and June 2020. The independent variable was the type of ovarian suppression, categorized as either OA (n = 174) or GnRHa (n = 389). Major depression was evaluated using the Patient Health Questionnaire (PHQ-9), and the Female Sexual Function Index questionnaire was used to assess sexual function.Results: A total of 563 patients completed the surveys. The mean PHQ-9 sum score was slightly lower in the GnRHa cohort than in the OA cohort (11.4 ± 5.7 vs. 12.8 ± 5.8, P = 0.079). There were significantly fewer patients with major depression (PHQ-9 ≥ 15) in the GnRHa cohort (31.1% vs. 40.2%, P = 0.025). Further, the duration of OFS was closely correlated with major depression, indicating a time-dependent trend [duration of OFS > 2 years vs. duration of OFS ≤ 2 years: Exp (B) = 1.651, P = 0.031]. Sexual dysfunction was negatively correlated with major depression [sexual dysfunction vs. normal: Exp (B) = 0.769, P = 0.046].Conclusions: This is the first study to demonstrate that GnRHa results in more favorable depression outcomes than OA. Moreover, most patients preferred alternatives to their OFS treatment. These findings can contribute to improving and alleviating the adverse effects of OFS.

scholarly journals Comprehensive profiles and diagnostic value of menopausal-specific gut microbiota in premenopausal breast cancer

2021 ◽  
Author(s):  
Ming-Feng Hou ◽  
Fu Ou-Yang ◽  
Chung-Liang Li ◽  
Fang-Ming Chen ◽  
Chieh-Han Chuang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gut Microbiota ◽  
Cancer Patients ◽  
Critical Role ◽  
Postmenopausal Breast Cancer ◽  
Diagnostic Value ◽  
Breast Cancer Patients ◽  
Premenopausal Breast Cancer ◽  
Α Diversity ◽  
Functional Pathways

AbstractIn Western countries, breast cancer tends to occur in older postmenopausal women. However, in Asian countries, the proportion of younger premenopausal breast cancer patients is increasing. Increasing evidence suggests that the gut microbiota plays a critical role in breast cancer. However, studies on the gut microbiota in the context of breast cancer have mainly focused on postmenopausal breast cancer. Little is known about the gut microbiota in the context of premenopausal breast cancer. This study aimed to comprehensively explore the gut microbial profiles, diagnostic value, and functional pathways in premenopausal breast cancer patients. Here, we analyzed 267 breast cancer patients with different menopausal statuses and age-matched female controls. The α-diversity was significantly reduced in premenopausal breast cancer patients, and the β-diversity differed significantly between breast cancer patients and controls. By performing multiple analyses and classification, 14 microbial markers were identified in the different menopausal statuses of breast cancer. Bacteroides fragilis was specifically found in young women of premenopausal statuses and Klebsiella pneumoniae in older women of postmenopausal statuses. In addition, menopausal-specific microbial markers could exhibit excellent discriminatory ability in distinguishing breast cancer patients from controls. Finally, the functional pathways differed between breast cancer patients and controls. Our findings provide the first evidence that the gut microbiota in premenopausal breast cancer patients differs from that in postmenopausal breast cancer patients and shed light on menopausal-specific microbial markers for diagnosis and investigation, ultimately providing a noninvasive approach for breast cancer detection and a novel strategy for preventing premenopausal breast cancer.

Recent Postmenopause, but Not ER Status, Identifies a Subset of Primary Breast Cancer Patients with a Higher Risk of Relapse

1996 ◽  
Vol 784 (1 Challenges an) ◽  
pp. 491-495 ◽  
Author(s):  
A. TRAINA ◽  
M. LIQUORI ◽  
R. CUSIMANO ◽  
C. CALABRIA ◽  
B. AGOSTARA ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Primary Breast Cancer ◽  
Breast Cancer Patients ◽  
Risk Of Relapse ◽  
Er Status

Comparison of early onset breast cancer patients to older premenopausal breast cancer patients

2010 ◽  
Vol 282 (4) ◽  
pp. 427-432 ◽  
Author(s):  
Dominic Varga ◽  
Jochem Koenig ◽  
Kathrin Kuhr ◽  
Kathrin Strunz ◽  
Verena Geyer ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Early Onset ◽  
Breast Cancer Patients ◽  
Early Onset Breast Cancer ◽  
Premenopausal Breast Cancer
Sign in / Sign up

Export Citation Format

Share Document